In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to EACVI Silver Members, Fellows of the ESC and Young combined Members

Fast-SENC quantifies right ventricular intramyocardial strain to assess subclinical RV dysfunction

Session Poster session 1

Speaker Moritz Montenbruck

Congress : EuroCMR 2019

  • Topic : imaging
  • Sub-topic : Cardiac Magnetic Resonance
  • Session type : Poster Session
  • FP Number : P140

Authors : H Steen (Hamburg,DE), M Montenbruck (Hamburg,DE), S Esch (Hamburg,DE), A Schwarz (Hamburg,DE), S Kelle (Berlin,DE), P Wuelfing (Hamburg,DE), F Andre (Heidelberg,DE), K Korosoglou (Weinheim,DE)

H Steen1 , M Montenbruck2 , S Esch2 , A Schwarz2 , S Kelle3 , P Wuelfing4 , F Andre5 , K Korosoglou6 , 1Marien hospital, Faculty of University hospital - Hamburg - Germany , 2Marien Hospital - Hamburg - Germany , 3Charite University Hospital - Berlin - Germany , 4Mammazentrum am Krankenhaus Jerusalem - Hamburg - Germany , 5University Hospital of Heidelberg - Heidelberg - Germany , 6GRN-Klinik Weinheim - Weinheim - Germany ,

European Heart Journal - Cardiovascular Imaging ( 2019 ) 20 ( Supplement 2 ), ii85


Right ventricular ejection fraction (RVEF) identifies reduced right-side cardiac function in symptomatic patients.  However, alternative metrics are needed to detect subclinical RV dysfunction before cardiac remodeling results in systemic damage.  Fast-SENC intramyocardial strain (fSENC) is a unique cardiac magnetic resonance imaging (CMR) modality that measures intramyocardial RV contraction in 1 heartbeat per image plane.  This prospective registry compares fSENC and RVEF in patients with documented pulmonary disease. 


A single center, prospective registry of MRI scans acquired with a 1.5T scanner were evaluated for conventional CMR diagnostics including RVEF.  In addition, fSENC scans were acquired and processed with the MyoStrain software to quantify intramyocardial RV strain.  Two short axis scans (basal & midventricular) were used to calculate strain in 6 longitudinal RV segments while two long axis scans (3-chamber & 4-chamber) were used to calculate 5 circumferential RV segments.  Two additional planes (2-chamber long axis & apical short axis) were included to also evaluate LV intramyocardial strain producing a total of 6 planes (3 short axis & 3 long axis) with 16 longitudinal LV segments and 21 circumferential LV segments.


A total of 95 scans in 76 patients with pulmonary disease (42% COPD, 25% pulmonary hypertension, 26% asthma, 6% pneumonia) were included in the study.  Patients had an average (± stdev) age of 46 (18) yrs and BMI of 26 (5) kg/m2 (65% arterial hypertension, 25% diabetes mellitus, 44% moderate or severe tricuspid valve regurgitation, 28% cancer, 13% atrial fibrillation, 33% coronary artery disease). Figure 1 shows the relationship between CMR RVEF in the y-axis versus RV GCS in the x-axis respectively.  A polynomial fit curve showed a nonlinear decline in CMR RVEF after RV GCS worsened to greater than -17% (r = 0.75); the polynomial fit curve for RV GLS had an r = 0.56.


fSENC detects subclinical RV and LV dysfunction before changes in ejection fraction in patients with pulmonary disease.  The ability to directly measure intramyocardial RV strain allows quantification of the impact of diseases, pharmacological therapies and device interventions on right ventricular function.

Based on your interests

Members get more

Join now
  • 1ESC Professional Members – access all resources from ESC Congress and ESC Asia with APSC & AFC
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s congress resources
  • 3Under 40 or in training - with a Combined Membership, access resources from all congresses
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are